![\"Inside](\"https:\/\/www.europesays.com\/dk\/wp-content\/uploads\/2026\/02\/3d786f4edf067724a252dfd201061b09.jpeg\")
Inside Biotech: Novo Nordisk cuts GLP-1 prices as pressure builds on obesity juggernaut Proactive uses images sourced from Shutterstock <\/p>\n Inside Biotech: Novo Nordisk cuts GLP-1 prices as pressure builds on obesity juggernaut Proactive uses images sourced from Shutterstock <\/p>\n
Novo Nordisk (NYSE:NVO)<\/a>\u2019s once-dominant position in the booming obesity drug market is facing its sternest test yet.<\/p>\n The Danish pharmaceutical giant announced today that it will cut US list prices for its blockbuster GLP-1 therapies<\/a> \u2014 including Wegovy and Ozempic \u2014 by up to 50%, a move that signals both political and competitive pressure on the sector\u2019s most dominant player. The decision comes as the company grapples with a bruising run of headlines: a disappointing late-stage trial for its next-generation obesity candidate CagriSema and renewed scrutiny of pricing across the US healthcare system.<\/p>\n Shares in the company fell about 3% on Tuesday, before the post-close announcement, and are down more than 22% over the past five trading sessions, reflecting investor unease about growth durability in what had been one of Europe\u2019s most reliable pharma stories.<\/p>\n Novo said it would significantly reduce US list prices for its GLP-1 portfolio, including Wegovy, Ozempic and the oral semaglutide Rybelsus, to a flat US$675 per month for each drug, down from about $1,350 for Wegovy and from about $1,000\u00a0for Ozempic and Rybelsus. While net prices after rebates have long been lower than headline figures, published list prices have drawn sustained political scrutiny and fuelled debate over affordability; the reset aims to ease out-of-pocket costs for patients with high-deductible or coinsurance insurance designs.<\/p>\n By slashing sticker prices, Novo appears to be pre-empting further regulatory intervention while also positioning itself more aggressively against chief rival Eli Lilly and Co (NYSE:LLY)<\/a>, whose tirzepatide-based therapy Zepbound has taken over as GLP-1 market leader.<\/p>\n The pricing move may also reflect a shift in the supply-demand dynamic. After two years of constrained manufacturing capacity and persistent shortages, incremental capacity expansions across the industry are gradually easing bottlenecks. In a more balanced market, pricing power becomes harder to defend.<\/p>\n For investors, the key question is margin impact. GLP-1 drugs have delivered extraordinary revenue and profit growth for Novo, underpinning a re-rating that briefly made it Europe\u2019s most valuable listed company. Lower list prices \u2014 even if partially offset by higher volumes \u2014 introduce uncertainty into medium-term earnings forecasts.<\/p>\n